Literature DB >> 8814072

Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis.

E Sakiniene1, T Bremell, A Tarkowski.   

Abstract

OBJECTIVE: To evaluate the combined effect of systemic corticosteroid and antibiotic therapy on the course of septic arthritis.
METHODS: The murine model of hematogenously acquired Staphylococcus aureus arthritis was used. Mice were treated with corticosteroids and antibiotics, and were followed up individually. Arthritis was evaluated clinically and histopathologically. Serum samples and bacterial isolates were also analyzed.
RESULTS: The prevalence of arthritis 14 days after the onset of the disease was 22% in the corticosteroid and antibiotic-treated group, as compared with 81% in the control (nontreated) group and 48% in the antibiotic-treated group. The severity of arthritis also decreased in the corticosteroid and antibiotic-treated group, as did the mortality rate. Immunohistochemical analysis revealed a dramatic decrease in T cells and macrophages in the synovium of mice that took the combined therapy. The mechanisms leading to this outcome include the inhibitory effect of corticosteroids on T cell and B cell proliferation and differentiation, such as suppression of interferon-gamma (IFN gamma) production. Serum levels of IFN gamma were decreased 4-fold in the antibiotic-treated group compared with the controls; a 15-fold decrease was observed in the corticosteroid and antibiotic-treated animals. In addition, serum NO3- was significantly decreased in mice treated with antibiotics (P < or = 0.05), as well as in mice treated with corticosteroids and antibiotics (P < or = 0.001).
CONCLUSION: Systemic corticosteroid administration along with antibiotic therapy had beneficial effects on the course and outcome of S aureus arthritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814072     DOI: 10.1002/art.1780390921

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  Rethinking Pyogenic Flexor Tenosynovitis: Biofilm Formation Treated in a Cadaveric Model.

Authors:  Constantinos Ketonis; Noreen J Hickock; Asif M Ilyas
Journal:  J Hand Microsurg       Date:  2017-11-27

Review 2.  Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions.

Authors:  Sarah E Rowe; Jenna E Beam; Brian P Conlon
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

3.  [Septic arthritis in adults].

Authors:  J Loock; N Haustedt; J Wollenhaupt
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  The surface protein Pls of methicillin-resistant Staphylococcus aureus is a virulence factor in septic arthritis.

Authors:  Elisabet Josefsson; Katri Juuti; Maria Bokarewa; Pentti Kuusela
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Neutralization of MMP-2 and TNFR1 Regulates the Severity of S. aureus-Induced Septic Arthritis by Differential Alteration of Local and Systemic Proinflammatory Cytokines in Mice.

Authors:  Sahin Sultana; Rana Adhikary; Biswadev Bishayi
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 6.  [Infections of non-prosthetically treated joints].

Authors:  O Hauschild; N P Südkamp
Journal:  Chirurg       Date:  2016-10       Impact factor: 0.955

7.  Azithromycin in combination with riboflavin decreases the severity of Staphylococcus aureus infection induced septic arthritis by modulating the production of free radicals and endogenous cytokines.

Authors:  Pinky Mal; Kallol Dutta; Debasish Bandyopadhyay; Anirban Basu; Rajni Khan; Biswadev Bishayi
Journal:  Inflamm Res       Date:  2012-11-15       Impact factor: 4.575

8.  Septic arthritis in the native joint.

Authors:  Meghan B Brennan; Jennifer L Hsu
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 9.  Clinical management of septic arthritis.

Authors:  Katie A Sharff; Eric P Richards; John M Townes
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

10.  Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.

Authors:  Ioannis Skiadas; Angelos Pefanis; Apostolos Papalois; Aspasia Kyroudi; Helen Triantafyllidi; Thomas Tsaganos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.